Biomarkers downregulated in prostate cancer

• US 8,008,012 B2
• Filed: 09/30/2008
• Issued: 08/30/2011
• Est. Priority Date: 01/24/2002
• Status: Expired due to Fees

• Current Assignee: Health Discovery Corporation
• Original Assignee: Health Discovery Corporation
• Inventors: Guyon, Isabelle
• Primary Examiner(s): Aeder; Sean
• Application Number:
  US12/242,912
• Publication Number:
  US 20090305257A1
• Time in Patent Office: 1,064 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: G06F 18/2115 by evaluating different subsets according to an optimisation criterion, e.g. class separability, forward selection or backward elimination

Abstract

Biomarkers are identified by analyzing gene expression data using support vector machines (SVM), recursive feature elimination (RFE) and/or linear ridge regression classifiers to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer.

Claims

1. A method for screening for the presence of prostate cancer in a patient comprising:

detecting within a patient sample comprising prostate cells each polynucleotide of a combination of polynucleotides consisting of SLC14A1 (SEQ ID NO.

     1), FER1L3 (SEQ ID NO.

     2) and ANXA6 (SEQ ID NO.

     3);

comparing levels of the polynucleotides to a control sample comprising prostate cells taken from a control subject not having prostate cancer, wherein the patient sample and the control sample are of a same sample type;

wherein decreased levels of each of the polynucleotides in the combination in the patient sample relative to the control sample are indicative of prostate cancer.

2. The method of claim 1, wherein the patient sample and the control sample each comprises serum containing prostate cells.

3. The method of claim 1, wherein the patient sample and the control sample each comprises semen containing prostate cells.

4. A method for screening for the presence of prostate cancer in a patient comprising:

detecting within a patient sample containing prostate cells underexpression relative to a non-cancer control sample containing prostate cells of each polynucleotide of a combination of polynucleotides comprising SLC14A1 (SEQ ID NO.

     1), FER1L3 (SEQ ID NO.

     2) and ANXA6 (SEQ ID NO.

     3), wherein the patient sample and the non-cancer control sample are of a same sample type.

5. The method of claim 4, wherein the patient sample and the non-cancer control sample each comprises serum.

6. The method of claim 4, wherein the patient sample and the non-cancer control sample each comprises semen.